Table 1.
Patients’ characteristics.
Table 2.
Laboratory findings at baseline.
Table 3.
Mean doses of erythropoiesis stimulating agent and intravenous iron, and mean hemoglobin levels over 24 weeks.
Fig 1.
Changes in hemoglobin (a), transferrin saturation (TSAT) (b), and ferritin (c) over 6 months among intact fibroblast growth factor 23 (i-FGF23) tertiles: closed circle, higher i-FGF23 tertile; open square, middle i-FGF23 tertile; open circle, lower i-FGF23 tertile.
Table 4.
Association of intact fibroblast growth factor 23 levels with doses of intravenous ferrotherapy over 24 weeks.